Amgen’s Repatha linked to fewer heart attacks while Novartis reports seven new tumor cases in Zolgensma patients

Amgen reported that its cholesterol‑lowering drug Repatha was associated with a lower incidence of heart attacks in a recent analysis. The data suggest the therapy may provide cardiovascular benefit beyond lipid reduction.

Novartis disclosed seven previously unreported tumor cases in children who received its gene therapy Zolgensma for spinal muscular atrophy. The company said the total number of tumor reports since the treatment’s 2019 approval now stands at nine.

The contrasting findings highlight ongoing safety monitoring for advanced therapies while underscoring the potential added value of established drugs in cardiovascular risk management.